Abstract
Multiplexed PCR amplicon sequencing (AmpSeq) is an increasingly popular application for cost-effective monitoring of threatened species and managed wildlife populations, and shows strong potential for genomic epidemiology of infectious disease. AmpSeq data for infectious microbes can inform disease control in multiple ways, including measuring drug resistance marker prevalence, distinguishing imported from local cases, and determining the effectiveness of therapeutics. We describe the design and comparative evaluation of two new AmpSeq assays for Plasmodium falciparum malaria parasites: a four-locus panel (‘4CAST’) composed of highly diverse antigens, and a 129-locus panel (‘AMPLseq’) composed of drug resistance markers, highly diverse loci for measuring relatedness, and a locus to detect Plasmodium vivax co-infections. We explore the performance of each panel in various public health use cases with in silico simulations as well as empirical experiments. We find that the smaller 4CAST panel performs reliably across a wide range of parasitemia levels without DNA pre-amplification, and could be highly informative for evaluating the number of distinct parasite strains within samples (complexity of infection), and distinguishing recrudescent infections from new infections in therapeutic efficacy studies. The AMPLseq panel performs similarly to two existing panels of comparable size for relatedness measurement, despite differences in the data and approach used for designing each panel. Finally, we describe an R package (paneljudge) that facilitates design and comparative evaluation of AmpSeq panels for relatedness estimation, and we provide general guidance on the design and implementation of AmpSeq panels for genomic epidemiology of infectious disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Grant Number U19AI110818 to the Broad Institute. This project was also supported by an NIH R01 award to DN (R01AI141544), an award from the Bill and Melinda Gates Foundation to DN and COB (OPP1213366), and a Broad Institute NextGen Award to BM. The Mali cohort study was funded by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. The Colombian cohort study was supported by British Council Newton-Caldas Fund Institutional Links Award G1854.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Kalifabougou cohort study was approved by the Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique and Technology of Bamako, and the Institutional Review Board of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH IRB protocol number: 11IN126; https://clinicaltrials.gov/; trial number NCT01322581). Written informed consent was obtained from participants or parents or guardians of participating children before inclusion in the study. The human subjects protocol for the Guyana sample collection was approved by the IRB of the Office of Human Research Administration at the Harvard Longwood Medical Area, as well as by a local ethical committee in Guyana.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All amplicon sequencing data, as well as WGS data from 16 Guyana samples, were submitted to the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) under accession PRJNA758191. This publication uses data from the MalariaGEN Plasmodium falciparum Community Project as described online pending publication and public release of dataset Pf7 (https://www.malariagen.net/resource/34); additional ENA accession numbers are available in Table S4. Previously published data from Guyana and French Guiana can be found at SRA BioProjects PRJNA543530 and PRJNA242182, respectively. Software and documentation can be found at https://github.com/broadinstitute/AmpSeQC (AmpSeQC pipeline), https://github.com/broadinstitute/malaria-amplicon-pipeline.git (Malaria amplicon pipeline), and https://github.com/artaylor85/paneljudge (paneljudge).
https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA758191
https://www.malariagen.net/resource/34
https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA543530
https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA242182
https://github.com/broadinstitute/AmpSeQC
https://github.com/broadinstitute/malaria-amplicon-pipeline.git
